<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00366899</url>
  </required_header>
  <id_info>
    <org_study_id>6096A1-500</org_study_id>
    <nct_id>NCT00366899</nct_id>
  </id_info>
  <brief_title>Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants</brief_title>
  <official_title>A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wyeth is now a wholly owned subsidiary of Pfizer</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability and immunogenicity of a
      13-valent pneumococcal conjugate (13vPnC) vaccine compared to Prevenar (7vPnC), when given
      concomitantly with routine paediatric vaccinations in Italy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Reporting Pre-Specified Local Reactions</measure>
    <time_frame>During the 4-day period after each dose</time_frame>
    <description>Local reactions were collected using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (&gt;7.0 cm). Participants may be represented in more than 1 category.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Reporting Pre-Specified Systemic Events</measure>
    <time_frame>During the 4-day period after each dose</time_frame>
    <description>Systemic events (fever ≥ 37.5 degrees Celsius [C], fever ≥ 38 C but ≤ 39 C, fever &gt;39 C but ≤ 40 C, fever &gt; 40 C, decreased appetite, irritability, increased sleep, decreased sleep, hives, use of medication (meds) to treat symptoms, and use of medication to prevent symptoms) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Predefined Antibody Levels for Concomitant Antigen Pertussis, Hepatitis B, Haemophilus Influenzae Type b, Diphtheria, Tetanus and Polio After the 2-Dose Infant Series and After the Toddler Dose</measure>
    <time_frame>One month after the infant series (6 months of age) and after the toddler dose (12 months of age)</time_frame>
    <description>Percentage of Participants achieving predefined antibody threshold levels for Pertussis Toxoid (PT) ≥5 ELISA units per milliliter (EU/mL), Filamentous Haemagglutinin (FHA) ≥5 or ≥7.82 EU/mL, and Pertactin (PRN) ≥5 EU/mL, ≥10.0 Milli-International Units Per Milliliter (mIU/mL) for Hepatitis B, Haemophilus Influenzae type b (Hib) 0.15 μg/ml, 0.01 or 0.1 IU/mL for Diphtheria, 0.1 IU/mL for Tetanus, and ≥1:8 titer for Polio (Type 1, 2, and 3) with the corresponding 95% CI for antigens are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Antibody Concentration (GMC) of Pertussis in the 13vPnC Group Relative to the 7vPnC Group After the 2-Dose Infant Series and After the Toddler Dose</measure>
    <time_frame>one month after infant series dose 2 (6 months of age) and after the toddler dose (12 months of age)</time_frame>
    <description>GMC of Pertussis (PT, FHA, PRN) were measured using an anti-Bordetella pertussis enzyme-linked immunosorbent assay (ELISA). Results were recorded in ELISA units per milliliter (EU/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Antibody Concentration (GMC) for Hepatitis B in the 13vPnC Group Relative to the 7vPnC Group After the 2-Dose Infant Series and After Toddler Dose</measure>
    <time_frame>One month after the infant series (6 months of age) and the toddler dose (12 months of age)</time_frame>
    <description>GMC of anti-hepatitis B surface antigen (HBsAg)using an Food and Drug Administration (FDA) approved in vitro diagnostic kit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Antibody Concentration (GMC) of Haemophilus Influenzae Type b (Hib) in the 13vPnC Group Relative to the 7vPnC Group After the 2-Dose Infant Series and After the Toddler Dose</measure>
    <time_frame>one month after infant series dose 2 (6 months of age) and after the toddler dose (12 months of age)</time_frame>
    <description>GMC for Hib polyribosylribitol phosphate as measured by ELISA, expressed in micrograms per milliliter (μg/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Antibody Concentration (GMC) of Diptheria and Tetanus in the 13vPnC Group Relative to the 7vPnC Group After the 2-Dose Infant Series and After the Toddler Dose</measure>
    <time_frame>one month after infant series dose 2 (6 months of age) and after the toddler dose (12 months of age)</time_frame>
    <description>GMC of anti-diphtheria and anti-tetanus toxoids as measured by ELISA (IU/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Antibody Concentration (GMC) of Polio Types 1, 2, and 3 in the 13vPnC Group Relative to the 7vPnC Group After the 2-Dose Infant Series and After the Toddler Dose</measure>
    <time_frame>one month after infant series dose 2 (6 months of age) and after the toddler dose (12 months of age)</time_frame>
    <description>GMC of Polio as measured using a polio in vitro plaque neutralization.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving an Antibody Level of ≥0.35 μg/mL in the 13vPnC Group After the 2-Dose Infant Series and Before the Toddler Dose</measure>
    <time_frame>one month after infant series dose 2 (6 months of age) and before the toddler dose (11 months of age)</time_frame>
    <description>Percentages of Participants achieving World Health Organization (WHO) predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody in 13vPnC Group After the 2-Dose Infant Series and Before Toddler Dose</measure>
    <time_frame>One month after infant series dose 2 (6 months of age) and before the toddler dose (11 months of age)</time_frame>
    <description>Antibody GMC for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving an Antibody Level of ≥0.35 μg/mL in the 13vPnC Relative to the 7vPnC Group After the Toddler Dose</measure>
    <time_frame>One month after the toddler dose (12 months of age)</time_frame>
    <description>Percentages of Participants achieving WHO predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody in 13vPnC Relative to 7vPnC Group After the Toddler Dose</measure>
    <time_frame>One month after toddler dose (12 months of age)</time_frame>
    <description>Antibody GMC for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Percentage of Subjects Achieving Antibody Titer (OPA) ≥1:8 in 13vPnC Group After the 2-Dose Infant Series and the Toddler Dose</measure>
    <time_frame>one month after infant series dose 2 and after the toddler dose</time_frame>
    <description>Percentage of subjects achieving functional antibody titer ≥1:8 as measured by opsonophagocytic activity assay (OPA) along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. (This is not a geometric mean comparison as suggested by the table row heading).</description>
  </other_outcome>
  <other_outcome>
    <measure>Geometric Mean Antibody Titer (OPA) in 13vPnC Group After the 2-Dose Infant Series and the Toddler Dose</measure>
    <time_frame>one month after infant series dose 2 and after the toddler dose</time_frame>
    <description>Antibody functionality/geometric mean titer (GMT) as measured by opsonophagocytic activity assay(OPA) for7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">605</enrollment>
  <condition>Vaccines, Pneumococcal</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>13-valent pneumococcal conjugate vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>7-valent pneumococcal conjugate vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>13-valent pneumococcal conjugate vaccine</intervention_name>
    <description>Single 0.5 mL dose of 13vPnC given at 3, 5 and 11 months of age.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>7 valent pneumococcal conjugate vaccine</intervention_name>
    <description>Single 0.5 mL dose of 7vPnC given at 3, 5 and 11 months of age.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Aged 3 months (75 to 105 days) at time of enrollment.

          2. Available for entire study period and whose parent(s)/legal guardian(s) could be
             reached by telephone.

          3. Healthy infant, as determined by medical history, physical examination, and judgment
             of the investigator.

          4. Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless
             of gestational age and birth weight, all subjects must have met inclusion criterion
             number 3.

          5. Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures
             during study participation.

        Exclusion criteria:

          1. Previous vaccination with licensed or investigational pneumococcal vaccine.

          2. Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or
             hepatitis B vaccines.

          3. A previous anaphylactic reaction to any vaccine or vaccine-related component.

          4. Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis,
             polio, or hepatitis B, or pneumococcal vaccines.

          5. Bleeding diathesis or condition associated with prolonged bleeding time that would
             contraindicate intramuscular injection.

          6. Known or suspected immune deficiency or suppression.

          7. History of culture-proven invasive disease caused by S pneumoniae or Hib.

          8. Major known congenital malformation or serious chronic disorder.

          9. Significant neurological disorder or history of seizure, including febrile seizure, or
             significant stable or evolving disorders, such as cerebral palsy, encephalopathy,
             hydrocephalus, or other significant disorders. Did not include resolving syndromes due
             to birth trauma such as Erb palsy.

         10. Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and
             monoclonal antibodies; eg, Synagis® [MedImmune]).

         11. Participation in another investigational trial. Participation in purely observational
             studies was acceptable.

         12. Infant who was a direct descendant (eg, child or grandchild) of the study site
             personnel.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>75 Days</minimum_age>
    <maximum_age>105 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Wyeth is now a wholly owned subsidiary of Pfizer</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Trial Manager</last_name>
    <role>Principal Investigator</role>
    <affiliation>For Italy, descresg@wyeth.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Napoli</city>
        <state>Campania</state>
        <zip>80122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Napoli</city>
        <state>Campania</state>
        <zip>80139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bologna</city>
        <state>Emilia Romagna</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Genova</city>
        <state>Liguria</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milan</city>
        <state>Lombardia</state>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Novara</city>
        <state>Piemonte</state>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taranto</city>
        <state>Puglia</state>
        <zip>74100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sassari</city>
        <state>Sardegna</state>
        <zip>07100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ragusa</city>
        <state>Sicilia</state>
        <zip>97100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palermo</city>
        <state>Sicillia</state>
        <zip>90100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Firenze</city>
        <state>Toscana</state>
        <zip>50132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2006</study_first_submitted>
  <study_first_submitted_qc>August 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 21, 2006</study_first_posted>
  <results_first_submitted>March 26, 2010</results_first_submitted>
  <results_first_submitted_qc>January 17, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 22, 2013</results_first_posted>
  <disposition_first_submitted>February 26, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>September 28, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 30, 2009</disposition_first_posted>
  <last_update_submitted>January 17, 2013</last_update_submitted>
  <last_update_submitted_qc>January 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 22, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vaccine</keyword>
  <keyword>Infants</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited in Italy from October 2006 to March 2007.</recruitment_details>
      <pre_assignment_details>Participants were enrolled into the study according to inclusion/exclusion criteria without a screening period. One subject was prerandomized and counted twice.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>13vPnC</title>
          <description>Participants received one single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) coadministered with diphtheria-tetanus-acellular pertussis (DTPa), hepatitis B, inactivated poliovirus, and hemophilus influenza type b (Hib) vaccine (Infanrix hexa) at 3 and 5 months (infant series), and 11 months of age (toddler dose).</description>
        </group>
        <group group_id="P2">
          <title>7vPnC</title>
          <description>Participants received one single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) coadministered with diphtheria-tetanus-acellular pertussis (DTPa), hepatitis B, inactivated poliovirus, and hemophilus influenza type b (Hib) vaccine (Infanrix hexa) at 3 and 5 months (infant series), and 11 months of age (toddler dose).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Infant Series</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="303">1 participant was counted twice, 1 participant randomized to 13vPnC, incorrectly received 7vPnC</participants>
                <participants group_id="P2" count="303">1 participant randomized to 7vPnC but never vaccinated</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated Dose 1</title>
              <participants_list>
                <participants group_id="P1" count="302">2 participants randomized to 13vPnC, incorrectly received 7vPnC</participants>
                <participants group_id="P2" count="302"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated Dose 2</title>
              <participants_list>
                <participants group_id="P1" count="296">1 participant randomized to 13vPnC, incorrectly received 7vPnC</participants>
                <participants group_id="P2" count="293"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="294"/>
                <participants group_id="P2" count="291"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failed to return</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized but not consented</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>After Infant Series</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="294"/>
                <participants group_id="P2" count="291"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="287"/>
                <participants group_id="P2" count="282"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Toddler Dose</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="287"/>
                <participants group_id="P2" count="282"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="285"/>
                <participants group_id="P2" count="281"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>13vPnC</title>
          <description>Participants received one single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) coadministered with diphtheria-tetanus-acellular pertussis (DTPa), hepatitis B, inactivated poliovirus, and hemophilus influenza type b (Hib) vaccine (Infanrix hexa) at 3 and 5 months (infant series), and 11 months of age (toddler dose).</description>
        </group>
        <group group_id="B2">
          <title>7vPnC</title>
          <description>Participants received one single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) coadministered with diphtheria-tetanus-acellular pertussis (DTPa), hepatitis B, inactivated poliovirus, and hemophilus influenza type b (Hib) vaccine (Infanrix hexa) at 3 and 5 months (infant series), and 11 months of age (toddler dose).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="303"/>
            <count group_id="B2" value="303"/>
            <count group_id="B3" value="606"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.9" spread="0.3"/>
                    <measurement group_id="B2" value="2.9" spread="0.3"/>
                    <measurement group_id="B3" value="2.9" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>1 gender unknown</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="138"/>
                    <measurement group_id="B2" value="133"/>
                    <measurement group_id="B3" value="271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="164"/>
                    <measurement group_id="B2" value="170"/>
                    <measurement group_id="B3" value="334"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Reporting Pre-Specified Local Reactions</title>
        <description>Local reactions were collected using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (&gt;7.0 cm). Participants may be represented in more than 1 category.</description>
        <time_frame>During the 4-day period after each dose</time_frame>
        <population>The safety population included all participants who received at least 1 dose of vaccine, (n) = number of participants reporting yes for at least 1 day or no for all days.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC Dose 1</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 3 months of age.</description>
          </group>
          <group group_id="O2">
            <title>7vPnC Dose 1</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with Infanrix hexa at 3 months of age.</description>
          </group>
          <group group_id="O3">
            <title>13vPnC Dose 2</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 5 months of age.</description>
          </group>
          <group group_id="O4">
            <title>7vPnC Dose 2</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with Infanrix hexa at 5 months of age.</description>
          </group>
          <group group_id="O5">
            <title>13vPnC Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 11 months of age.</description>
          </group>
          <group group_id="O6">
            <title>7vPnC Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with Infanrix hexa at 11 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-Specified Local Reactions</title>
          <description>Local reactions were collected using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (&gt;7.0 cm). Participants may be represented in more than 1 category.</description>
          <population>The safety population included all participants who received at least 1 dose of vaccine, (n) = number of participants reporting yes for at least 1 day or no for all days.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="302"/>
                <count group_id="O3" value="296"/>
                <count group_id="O4" value="293"/>
                <count group_id="O5" value="294"/>
                <count group_id="O6" value="291"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tenderness - Any (n=234,243,214,215,199,188)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.1"/>
                    <measurement group_id="O2" value="30.0"/>
                    <measurement group_id="O3" value="30.4"/>
                    <measurement group_id="O4" value="36.7"/>
                    <measurement group_id="O5" value="47.2"/>
                    <measurement group_id="O6" value="44.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness-Significant (n=224,231,199,199,164,153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7"/>
                    <measurement group_id="O2" value="3.5"/>
                    <measurement group_id="O3" value="4.5"/>
                    <measurement group_id="O4" value="5.0"/>
                    <measurement group_id="O5" value="8.5"/>
                    <measurement group_id="O6" value="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling - Any (n=232,240,207,209,175,165)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0"/>
                    <measurement group_id="O2" value="19.6"/>
                    <measurement group_id="O3" value="24.6"/>
                    <measurement group_id="O4" value="28.7"/>
                    <measurement group_id="O5" value="28.6"/>
                    <measurement group_id="O6" value="27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling - Mild (n=232,240,207,208,174,161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.7"/>
                    <measurement group_id="O2" value="18.3"/>
                    <measurement group_id="O3" value="21.7"/>
                    <measurement group_id="O4" value="26.4"/>
                    <measurement group_id="O5" value="26.4"/>
                    <measurement group_id="O6" value="21.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling - Moderate (n=223,229,198,195,160,157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6"/>
                    <measurement group_id="O2" value="3.1"/>
                    <measurement group_id="O3" value="5.6"/>
                    <measurement group_id="O4" value="5.1"/>
                    <measurement group_id="O5" value="7.5"/>
                    <measurement group_id="O6" value="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling - Severe (n=222,229,197,194,159,152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness - Any (n=233,245,213,212,178,174)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.8"/>
                    <measurement group_id="O2" value="26.5"/>
                    <measurement group_id="O3" value="31.5"/>
                    <measurement group_id="O4" value="34.4"/>
                    <measurement group_id="O5" value="36.5"/>
                    <measurement group_id="O6" value="36.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness - Mild (n=233,244,211,211,178,172)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.0"/>
                    <measurement group_id="O2" value="24.6"/>
                    <measurement group_id="O3" value="28.4"/>
                    <measurement group_id="O4" value="32.2"/>
                    <measurement group_id="O5" value="32.6"/>
                    <measurement group_id="O6" value="30.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness - Moderate (n=222,231,200,195,160,156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7"/>
                    <measurement group_id="O2" value="3.0"/>
                    <measurement group_id="O3" value="5.5"/>
                    <measurement group_id="O4" value="3.6"/>
                    <measurement group_id="O5" value="7.5"/>
                    <measurement group_id="O6" value="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness - Severe (n=243,255,197,194,159,152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Reporting Pre-Specified Systemic Events</title>
        <description>Systemic events (fever ≥ 37.5 degrees Celsius [C], fever ≥ 38 C but ≤ 39 C, fever &gt;39 C but ≤ 40 C, fever &gt; 40 C, decreased appetite, irritability, increased sleep, decreased sleep, hives, use of medication (meds) to treat symptoms, and use of medication to prevent symptoms) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
        <time_frame>During the 4-day period after each dose</time_frame>
        <population>The safety population included all subjects who received at least 1 dose of vaccine, (n) = number of participants reporting yes for at least 1 day or no for all days.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC Dose 1</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 3 months of age.</description>
          </group>
          <group group_id="O2">
            <title>7vPnC Dose 1</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with Infanrix hexa at 3 months of age.</description>
          </group>
          <group group_id="O3">
            <title>13vPnC Dose 2</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 5 months of age.</description>
          </group>
          <group group_id="O4">
            <title>7vPnC Dose 2</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with Infanrix hexa at 5 months of age.</description>
          </group>
          <group group_id="O5">
            <title>13vPnC Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 11 months of age.</description>
          </group>
          <group group_id="O6">
            <title>7vPnC Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with Infanrix hexa at 11 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-Specified Systemic Events</title>
          <description>Systemic events (fever ≥ 37.5 degrees Celsius [C], fever ≥ 38 C but ≤ 39 C, fever &gt;39 C but ≤ 40 C, fever &gt; 40 C, decreased appetite, irritability, increased sleep, decreased sleep, hives, use of medication (meds) to treat symptoms, and use of medication to prevent symptoms) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
          <population>The safety population included all subjects who received at least 1 dose of vaccine, (n) = number of participants reporting yes for at least 1 day or no for all days.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="302"/>
                <count group_id="O3" value="296"/>
                <count group_id="O4" value="293"/>
                <count group_id="O5" value="294"/>
                <count group_id="O6" value="291"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever ≥38°C but ≤39°C (n=247,246,227,226,204,197)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.7"/>
                    <measurement group_id="O2" value="38.6"/>
                    <measurement group_id="O3" value="55.5"/>
                    <measurement group_id="O4" value="60.6"/>
                    <measurement group_id="O5" value="63.7"/>
                    <measurement group_id="O6" value="52.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;39°C but ≤40°C (n=224,233,204,201,167,160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6"/>
                    <measurement group_id="O2" value="4.7"/>
                    <measurement group_id="O3" value="6.9"/>
                    <measurement group_id="O4" value="7.0"/>
                    <measurement group_id="O5" value="9.6"/>
                    <measurement group_id="O6" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;40°C (n=222,230,198,195,160,152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased appetite (n=246,248,220,218,198,197)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.4"/>
                    <measurement group_id="O2" value="34.3"/>
                    <measurement group_id="O3" value="47.3"/>
                    <measurement group_id="O4" value="45.4"/>
                    <measurement group_id="O5" value="52.0"/>
                    <measurement group_id="O6" value="57.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability (n=258,259,245,243,221,227)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.9"/>
                    <measurement group_id="O2" value="63.7"/>
                    <measurement group_id="O3" value="75.5"/>
                    <measurement group_id="O4" value="75.3"/>
                    <measurement group_id="O5" value="74.7"/>
                    <measurement group_id="O6" value="74.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased sleep (n=269,276,226,232,195,196)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.8"/>
                    <measurement group_id="O2" value="64.5"/>
                    <measurement group_id="O3" value="57.1"/>
                    <measurement group_id="O4" value="56.5"/>
                    <measurement group_id="O5" value="53.8"/>
                    <measurement group_id="O6" value="54.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased sleep (n=244,242,222,213,180,171)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.3"/>
                    <measurement group_id="O2" value="36.4"/>
                    <measurement group_id="O3" value="40.1"/>
                    <measurement group_id="O4" value="41.8"/>
                    <measurement group_id="O5" value="35.6"/>
                    <measurement group_id="O6" value="35.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meds-treat symptoms (n=244,245,219,109,192,190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.8"/>
                    <measurement group_id="O2" value="30.6"/>
                    <measurement group_id="O3" value="43.4"/>
                    <measurement group_id="O4" value="47.8"/>
                    <measurement group_id="O5" value="53.1"/>
                    <measurement group_id="O6" value="43.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meds-prevent symptoms (n=230,238,208,208,172,169)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.6"/>
                    <measurement group_id="O2" value="18.1"/>
                    <measurement group_id="O3" value="20.2"/>
                    <measurement group_id="O4" value="24.5"/>
                    <measurement group_id="O5" value="27.9"/>
                    <measurement group_id="O6" value="24.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving Predefined Antibody Levels for Concomitant Antigen Pertussis, Hepatitis B, Haemophilus Influenzae Type b, Diphtheria, Tetanus and Polio After the 2-Dose Infant Series and After the Toddler Dose</title>
        <description>Percentage of Participants achieving predefined antibody threshold levels for Pertussis Toxoid (PT) ≥5 ELISA units per milliliter (EU/mL), Filamentous Haemagglutinin (FHA) ≥5 or ≥7.82 EU/mL, and Pertactin (PRN) ≥5 EU/mL, ≥10.0 Milli-International Units Per Milliliter (mIU/mL) for Hepatitis B, Haemophilus Influenzae type b (Hib) 0.15 μg/ml, 0.01 or 0.1 IU/mL for Diphtheria, 0.1 IU/mL for Tetanus, and ≥1:8 titer for Polio (Type 1, 2, and 3) with the corresponding 95% CI for antigens are presented.</description>
        <time_frame>One month after the infant series (6 months of age) and after the toddler dose (12 months of age)</time_frame>
        <population>Evaluable immunogenicity (per protocol) population who adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations; (n) = number of participants with a determinate postinfant antibody concentration/titer for the given concomitant antigen.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC After 2-Dose Infant Series</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 3 and 5 months of age (infant series).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC After 2-Dose Infant Series</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with Infanrix hexa at 3 and 5 months of age (infant series).</description>
          </group>
          <group group_id="O3">
            <title>13vPnC After Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 11 months of age (toddler dose).</description>
          </group>
          <group group_id="O4">
            <title>7vPnC After Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with Infanrix hexa at 11 months of age (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Predefined Antibody Levels for Concomitant Antigen Pertussis, Hepatitis B, Haemophilus Influenzae Type b, Diphtheria, Tetanus and Polio After the 2-Dose Infant Series and After the Toddler Dose</title>
          <description>Percentage of Participants achieving predefined antibody threshold levels for Pertussis Toxoid (PT) ≥5 ELISA units per milliliter (EU/mL), Filamentous Haemagglutinin (FHA) ≥5 or ≥7.82 EU/mL, and Pertactin (PRN) ≥5 EU/mL, ≥10.0 Milli-International Units Per Milliliter (mIU/mL) for Hepatitis B, Haemophilus Influenzae type b (Hib) 0.15 μg/ml, 0.01 or 0.1 IU/mL for Diphtheria, 0.1 IU/mL for Tetanus, and ≥1:8 titer for Polio (Type 1, 2, and 3) with the corresponding 95% CI for antigens are presented.</description>
          <population>Evaluable immunogenicity (per protocol) population who adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations; (n) = number of participants with a determinate postinfant antibody concentration/titer for the given concomitant antigen.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="275"/>
                <count group_id="O2" value="279"/>
                <count group_id="O3" value="254"/>
                <count group_id="O4" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pertussis, PT ≥5 EU/mL (n=250,272,235,219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.6" lower_limit="97.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="98.7" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="98.4" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100.0" lower_limit="98.3" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertussis, FHA ≥5 EU/mL (n=243,272,229,214)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="98.7" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="98.4" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100.0" lower_limit="98.3" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertussis, FHA ≥7.82 EU/mL (n=243,272,229,214)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="98.7" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="98.4" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100.0" lower_limit="98.3" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertactin ≥5 EU/mL (n=248,270,234,217)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="98.6" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="98.4" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100.0" lower_limit="98.3" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatitis B ≥ 10.0 mIU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.8" lower_limit="90.2" upper_limit="96.3"/>
                    <measurement group_id="O2" value="93.1" lower_limit="89.5" upper_limit="95.8"/>
                    <measurement group_id="O3" value="98.40" lower_limit="96.00" upper_limit="99.60"/>
                    <measurement group_id="O4" value="98.80" lower_limit="96.60" upper_limit="99.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Haemophilus Influenzae type b 0.15 μg/ml</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.0" lower_limit="82.0" upper_limit="91.1"/>
                    <measurement group_id="O2" value="90.3" lower_limit="86.1" upper_limit="93.5"/>
                    <measurement group_id="O3" value="99.6" lower_limit="97.7" upper_limit="100.0"/>
                    <measurement group_id="O4" value="98.2" lower_limit="95.4" upper_limit="99.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Haemophilus Influenzae type b 1.0 μg/ml</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.9" lower_limit="42.7" upper_limit="56.0"/>
                    <measurement group_id="O2" value="48.7" lower_limit="42.6" upper_limit="54.9"/>
                    <measurement group_id="O3" value="96.2" lower_limit="92.9" upper_limit="98.2"/>
                    <measurement group_id="O4" value="92.2" lower_limit="87.8" upper_limit="95.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diptheria 0.01 IU/mL (n=207,240,164,190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.2" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="98.5" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="97.8" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100.0" lower_limit="98.1" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diptheria 0.1 IU/mL (n=207,240,164,190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.8" lower_limit="88.3" upper_limit="95.9"/>
                    <measurement group_id="O2" value="96.3" lower_limit="93.0" upper_limit="98.3"/>
                    <measurement group_id="O3" value="100.0" lower_limit="97.8" upper_limit="100"/>
                    <measurement group_id="O4" value="100.0" lower_limit="98.1" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tetanus 0.1 IU/mL (n=155,214,125,96)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.2" lower_limit="89.3" upper_limit="97.3"/>
                    <measurement group_id="O2" value="92.5" lower_limit="88.1" upper_limit="95.7"/>
                    <measurement group_id="O3" value="97.6" lower_limit="93.1" upper_limit="99.5"/>
                    <measurement group_id="O4" value="93.8" lower_limit="86.9" upper_limit="97.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Polio, Type 1 ≥1:8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.5" lower_limit="97.3" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.6" lower_limit="97.9" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="97.9" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100.0" lower_limit="98.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Polio, Type 2 ≥1:8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.6" lower_limit="91.8" upper_limit="98.0"/>
                    <measurement group_id="O2" value="96.6" lower_limit="93.6" upper_limit="98.4"/>
                    <measurement group_id="O3" value="100.0" lower_limit="97.6" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100.0" lower_limit="97.9" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Polio, Type 3 ≥1:8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.5" lower_limit="97.3" upper_limit="100.0"/>
                    <measurement group_id="O2" value="98.9" lower_limit="96.7" upper_limit="99.8"/>
                    <measurement group_id="O3" value="100.0" lower_limit="97.6" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100.0" lower_limit="97.9" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertussis, PT (infant ≥16; Toddler ≥21) EU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.2" lower_limit="91.8" upper_limit="97.5"/>
                    <measurement group_id="O2" value="95.2" lower_limit="92.0" upper_limit="97.4"/>
                    <measurement group_id="O3" value="92.8" lower_limit="88.7" upper_limit="95.7"/>
                    <measurement group_id="O4" value="95.4" lower_limit="91.8" upper_limit="97.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertussis, FHA (Infant ≥31; Toddler ≥162) EU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.7" lower_limit="91.0" upper_limit="97.1"/>
                    <measurement group_id="O2" value="95.6" lower_limit="92.4" upper_limit="97.7"/>
                    <measurement group_id="O3" value="95.2" lower_limit="91.6" upper_limit="97.6"/>
                    <measurement group_id="O4" value="95.3" lower_limit="91.6" upper_limit="97.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertactin (Infant ≥40; Toddler ≥106) EU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.9" lower_limit="87.8" upper_limit="95.0"/>
                    <measurement group_id="O2" value="95.2" lower_limit="91.9" upper_limit="97.4"/>
                    <measurement group_id="O3" value="94.9" lower_limit="91.2" upper_limit="97.3"/>
                    <measurement group_id="O4" value="95.4" lower_limit="91.7" upper_limit="97.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Pertussis PT the difference in percentages between the two groups (13vPnC – 7vPnC) at ≥5 EU/mL threshold was calculated.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of the 2-sided 95% CI for the difference between the two groups was &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.2</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Pertussis PT the difference in percentages between the two groups (13vPnC – 7vPnC) at ≥16 EU/mL threshold was calculated.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of the 2-sided 95% CI for the difference between the two groups was &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.0</ci_lower_limit>
            <ci_upper_limit>3.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Pertussis FHA the difference in percentages between the two groups (13vPnC - 7vPnC) at ≥5 EU/mL threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of the 2-sided 95% CI for the difference between the two groups was &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.6</ci_lower_limit>
            <ci_upper_limit>1.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Pertussis FHA the difference in percentages between the two groups (13vPnC – 7vPnC) at ≥7.82 EU/mL threshold was calculated.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of the 2-sided 95% CI for the difference between the two groups was &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.6</ci_lower_limit>
            <ci_upper_limit>1.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Pertussis FHA the difference in percentages between the two groups ( 13vPnC - 7vPnC) at ≥31 EU/mL threshold was calculated.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of the 2-sided 95% CI for the difference between the two groups was &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-5.0</ci_lower_limit>
            <ci_upper_limit>2.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Pertactin the difference in percentages between the two groups (13vPnC - 7vPnC) at ≥5 EU/mL threshold was calculated.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of the 2-sided 95% CI for the difference between the two groups was &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.5</ci_lower_limit>
            <ci_upper_limit>1.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Pertactin the difference in percentages between the two groups ( 13vPnC - 7vPnC) at ≥40 EU/mL threshold was calculated.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of the 2-sided 95% CI for the difference between the two groups was &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-3.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-7.8</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For hepatitis B the difference in percentages between the two groups (13vPnC – 7vPnC) at ≥10.0 mIU/mL threshold was calculated.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of the 2-sided 95% CI for the difference between the two groups was &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.6</ci_lower_limit>
            <ci_upper_limit>5.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Haemophilus influenzae type b the difference in percentages between the two groups (13vPnC – 7vPnC) at 0.15 μg/mL threshold was calculated.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of the 2-sided 95% CI for the difference between the two groups was &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-3.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-9.1</ci_lower_limit>
            <ci_upper_limit>2.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Haemophilus influenzae type b the difference in percentages between the two groups (13vPnC – 7vPnC) at 1.0 μg/mL threshold was calculated.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of the 2-sided 95% CI for the difference between the two groups was &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-8.2</ci_lower_limit>
            <ci_upper_limit>9.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Diptheria the difference in percentages between the two groups ( 13vPnC – 7vPnC) at 0.01 IU/mL threshold was calculated.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of the 2-sided 95% CI for the difference between the two groups was &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.8</ci_lower_limit>
            <ci_upper_limit>1.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Diptheria the difference in percentage between the two groups ( 13vPnC – 7vPnC) at 0.1 IU/mL threshold was calculated.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of the 2-sided 95% CI for the difference between the two groups was &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-3.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-8.3</ci_lower_limit>
            <ci_upper_limit>0.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Tetanus the difference in percentage between the two groups ( 13vPnC – 7vPnC) at 0.1 IU/mL threshold was calculated.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of the 2-sided 95% CI for the difference between the two groups was &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>1.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.9</ci_lower_limit>
            <ci_upper_limit>7.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Polio Type 1 the difference in percentage between the two groups (13vPnC – 7vPnC) at ≥1:8 threshold was calculated.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of the 2-sided 95% CI for the difference between the two groups was &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.3</ci_lower_limit>
            <ci_upper_limit>1.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Polio Type 2 the difference in percentage between the two groups ( 13vPnC – 7vPnC) at ≥1:8 threshold was calculated.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of the 2-sided 95% CI for the difference between the two groups was &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-5.0</ci_lower_limit>
            <ci_upper_limit>2.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Polio Type 3 the difference in percentages between the two groups (13vPnC – 7vPnC) at ≥1:8 threshold was calculated.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of the 2-sided 95% CI for the difference between the two groups was &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.6</ci_lower_limit>
            <ci_upper_limit>2.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Pertussis PT the difference in percentages between the two groups (13vPnC - 7vPnC) at ≥5 EU/mL threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of the 2-sided 95% CI for the difference between the two groups was &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.6</ci_lower_limit>
            <ci_upper_limit>1.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Pertussis PT the difference in percentages between the two groups (13vPnC - 7vPnC) at ≥21 EU/mL threshold was calculated.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of the 2-sided 95% CI for the difference between the two groups was &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-2.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-7.3</ci_lower_limit>
            <ci_upper_limit>1.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Pertussis FHA the difference in percentages between the two groups (13vPnC - 7vPnC) at ≥5 EU/mL threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of the 2-sided 95% CI for the difference between the two groups was &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.6</ci_lower_limit>
            <ci_upper_limit>1.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Pertussis FHA the difference in percentages between the two groups (13vPnC - 7vPnC) at ≥7.82 EU/mL threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of the 2-sided 95% CI for the difference between the two groups was &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.6</ci_lower_limit>
            <ci_upper_limit>1.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Pertussis FHA the difference in percentages between the two groups (13vPnC - 7vPnC) at ≥162 EU/mL threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of the 2-sided 95% CI for the difference between the two groups was &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.3</ci_lower_limit>
            <ci_upper_limit>4.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Pertactin the difference in percentages between the two groups (13vPnC - 7vPnC) at ≥5 EU/mL threshold was calculated.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of the 2-sided 95% CI for the difference between the two groups was &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.6</ci_lower_limit>
            <ci_upper_limit>1.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Pertactin the difference in percentages between the two groups (13vPnC - 7vPnC) at ≥106 EU/mL threshold was calculated.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of the 2-sided 95% CI for the difference between the two groups was &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.7</ci_lower_limit>
            <ci_upper_limit>3.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For hepatitis B the difference in percentages between the two groups (13vPnC - 7vPnC) at ≥10.0 mIU/mL threshold was calculated.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of the 2-sided 95% CI for the difference between the two groups was &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.0</ci_lower_limit>
            <ci_upper_limit>2.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Haemophilus influenzae type b the difference in percentage between the two groups (13vPnC - 7vPnC) at 0.15 μg/mL threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of the 2-sided 95% CI for the difference between the two groups was &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.8</ci_lower_limit>
            <ci_upper_limit>4.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Haemophilus influenzae type b the difference in percentage between the two groups (13vPnC - 7vPnC) at 1.0 μg/mL threshold was calculated.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of the 2-sided 95% CI for the difference between the two groups was &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>4.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>8.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Diphtheria the difference in percentages between the two groups (13vPnC - 7vPnC) at 0.01 IU/mL threshold was calculated.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of the 2-sided 95% CI for the difference between the two groups was &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.3</ci_lower_limit>
            <ci_upper_limit>2.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Diphtheria the difference in percentages between the two groups (13vPnC - 7vPnC) at 0.1 IU/mL threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of the 2-sided 95% CI for the difference between the two groups was &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.3</ci_lower_limit>
            <ci_upper_limit>2.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Tetanus the difference in percentages between the two groups (13vPnC - 7vPnC) at 0.1 IU/mL threshold was calculated.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of the 2-sided 95% CI for the difference between the two groups was &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>3.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.7</ci_lower_limit>
            <ci_upper_limit>10.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Polio Type 1 the difference in percentage between the two groups (13vPnC - 7vPnC) at ≥1:8 threshold was calculated.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of the 2-sided 95% CI for the difference between the two groups was &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.4</ci_lower_limit>
            <ci_upper_limit>2.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Polio Type 2 the difference in percentage between the two groups (13vPnC - 7vPnC) at ≥1:8 threshold was calculated.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of the 2-sided 95% CI for the difference between the two groups was &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.4</ci_lower_limit>
            <ci_upper_limit>2.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Polio Type 3 the difference in percentage between the two groups (13vPnC - 7vPnC) at ≥1:8 threshold was calculated.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of the 2-sided 95% CI for the difference between the two groups was &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.4</ci_lower_limit>
            <ci_upper_limit>2.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Antibody Concentration (GMC) of Pertussis in the 13vPnC Group Relative to the 7vPnC Group After the 2-Dose Infant Series and After the Toddler Dose</title>
        <description>GMC of Pertussis (PT, FHA, PRN) were measured using an anti-Bordetella pertussis enzyme-linked immunosorbent assay (ELISA). Results were recorded in ELISA units per milliliter (EU/mL)</description>
        <time_frame>one month after infant series dose 2 (6 months of age) and after the toddler dose (12 months of age)</time_frame>
        <population>Evaluable immunogenicity (per protocol) population adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC After 2-Dose Infant Series</title>
            <description>Subjects received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 3 and 5 months of age (infant series).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC After 2-Dose Infant Series</title>
            <description>Subjects received one single 0.5 mL dose of 7vPnC coadministered with Infanrix hexa at 3 and 5 months of age (infant series).</description>
          </group>
          <group group_id="O3">
            <title>13vPnC After Toddler Dose</title>
            <description>Subjects received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 11 months of age (toddler dose).</description>
          </group>
          <group group_id="O4">
            <title>7vPnC After Toddler Dose</title>
            <description>Subjects received one single 0.5 mL dose of 7vPnC coadministered with Infanrix hexa at 11 months of age (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Antibody Concentration (GMC) of Pertussis in the 13vPnC Group Relative to the 7vPnC Group After the 2-Dose Infant Series and After the Toddler Dose</title>
          <description>GMC of Pertussis (PT, FHA, PRN) were measured using an anti-Bordetella pertussis enzyme-linked immunosorbent assay (ELISA). Results were recorded in ELISA units per milliliter (EU/mL)</description>
          <population>Evaluable immunogenicity (per protocol) population adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations.</population>
          <units>EU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="275"/>
                <count group_id="O2" value="279"/>
                <count group_id="O3" value="254"/>
                <count group_id="O4" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pertussis FHA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102.87" lower_limit="94.35" upper_limit="112.16"/>
                    <measurement group_id="O2" value="105.17" lower_limit="97.25" upper_limit="113.73"/>
                    <measurement group_id="O3" value="463.23" lower_limit="425.19" upper_limit="504.67"/>
                    <measurement group_id="O4" value="456.55" lower_limit="415.06" upper_limit="502.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertussis PT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.01" lower_limit="45.82" upper_limit="54.58"/>
                    <measurement group_id="O2" value="48.44" lower_limit="44.71" upper_limit="52.49"/>
                    <measurement group_id="O3" value="60.89" lower_limit="55.61" upper_limit="66.67"/>
                    <measurement group_id="O4" value="64.53" lower_limit="59.13" upper_limit="70.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertussis PRN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="167.76" lower_limit="149.54" upper_limit="188.18"/>
                    <measurement group_id="O2" value="166.19" lower_limit="150.28" upper_limit="183.78"/>
                    <measurement group_id="O3" value="339.30" lower_limit="309.16" upper_limit="372.38"/>
                    <measurement group_id="O4" value="361.70" lower_limit="328.59" upper_limit="398.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Pertussis FHA the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMC/GMT ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Pertussis PT the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMC/GMT ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.92</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Pertussis PRN the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMC/GMT ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Pertussis FHA the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMC/GMT ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Pertussis PT the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMC/GMT ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Pertussis PRN the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMC/GMT ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Subjects Achieving Antibody Titer (OPA) ≥1:8 in 13vPnC Group After the 2-Dose Infant Series and the Toddler Dose</title>
        <description>Percentage of subjects achieving functional antibody titer ≥1:8 as measured by opsonophagocytic activity assay (OPA) along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. (This is not a geometric mean comparison as suggested by the table row heading).</description>
        <time_frame>one month after infant series dose 2 and after the toddler dose</time_frame>
        <population>OPAs were done in a subset of approximately 100 subjects (range 90-100 per serotype) in the 13vPnC group</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC After 2-Dose Infant Series</title>
            <description>Subjects received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 3 and 5 months of age (infant series).</description>
          </group>
          <group group_id="O2">
            <title>13vPnC After Toddler Dose</title>
            <description>Subjects received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 11 months of age (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Achieving Antibody Titer (OPA) ≥1:8 in 13vPnC Group After the 2-Dose Infant Series and the Toddler Dose</title>
          <description>Percentage of subjects achieving functional antibody titer ≥1:8 as measured by opsonophagocytic activity assay (OPA) along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. (This is not a geometric mean comparison as suggested by the table row heading).</description>
          <population>OPAs were done in a subset of approximately 100 subjects (range 90-100 per serotype) in the 13vPnC group</population>
          <units>% Achieving OPA Titer ≥1:8</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common Serotypes - Serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="96.3" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="95.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.0" lower_limit="82.4" upper_limit="95.1"/>
                    <measurement group_id="O2" value="99.0" lower_limit="94.3" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="96.3" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="96.1" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="96.3" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="96.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.0" lower_limit="91.4" upper_limit="99.4"/>
                    <measurement group_id="O2" value="100.0" lower_limit="96.3" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.0" lower_limit="90.1" upper_limit="98.9"/>
                    <measurement group_id="O2" value="97.9" lower_limit="92.7" upper_limit="99.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.0" lower_limit="91.4" upper_limit="99.4"/>
                    <measurement group_id="O2" value="100.0" lower_limit="96.3" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.8" lower_limit="88.3" upper_limit="98.3"/>
                    <measurement group_id="O2" value="100.0" lower_limit="96.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.0" lower_limit="94.6" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="96.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.0" lower_limit="90.0" upper_limit="98.9"/>
                    <measurement group_id="O2" value="100.0" lower_limit="96.1" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.9" lower_limit="89.9" upper_limit="98.9"/>
                    <measurement group_id="O2" value="100.0" lower_limit="96.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="96.4" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="96.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.6" lower_limit="89.0" upper_limit="98.8"/>
                    <measurement group_id="O2" value="100.0" lower_limit="96.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Geometric Mean Antibody Titer (OPA) in 13vPnC Group After the 2-Dose Infant Series and the Toddler Dose</title>
        <description>Antibody functionality/geometric mean titer (GMT) as measured by opsonophagocytic activity assay(OPA) for7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
        <time_frame>one month after infant series dose 2 and after the toddler dose</time_frame>
        <population>OPAS were done in a subset of approximately 100 subjects (range 90-100 per serotype) in the 13vPnC group</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC After 2-Dose Infant Series</title>
            <description>Subjects received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 3 and 5 months of age (infant series).</description>
          </group>
          <group group_id="O2">
            <title>13vPnC After Toddler Dose</title>
            <description>Subjects received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 11 months of age (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Antibody Titer (OPA) in 13vPnC Group After the 2-Dose Infant Series and the Toddler Dose</title>
          <description>Antibody functionality/geometric mean titer (GMT) as measured by opsonophagocytic activity assay(OPA) for7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
          <population>OPAS were done in a subset of approximately 100 subjects (range 90-100 per serotype) in the 13vPnC group</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common Serotypes - Serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="526.69" lower_limit="431.88" upper_limit="642.32"/>
                    <measurement group_id="O2" value="1276.21" lower_limit="1025.09" upper_limit="1588.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="191.34" lower_limit="133.35" upper_limit="274.55"/>
                    <measurement group_id="O2" value="2383.31" lower_limit="1850.47" upper_limit="3069.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3585.80" lower_limit="2787.34" upper_limit="4612.99"/>
                    <measurement group_id="O2" value="16384.00" lower_limit="13066.97" upper_limit="20543.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1882.96" lower_limit="1446.51" upper_limit="2451.10"/>
                    <measurement group_id="O2" value="1903.89" lower_limit="1580.90" upper_limit="2292.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="294.48" lower_limit="221.80" upper_limit="390.98"/>
                    <measurement group_id="O2" value="1324.41" lower_limit="1063.57" upper_limit="1649.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="222.86" lower_limit="170.46" upper_limit="291.37"/>
                    <measurement group_id="O2" value="391.97" lower_limit="296.34" upper_limit="518.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="487.51" lower_limit="356.25" upper_limit="667.13"/>
                    <measurement group_id="O2" value="3679.67" lower_limit="2971.61" upper_limit="4556.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.63" lower_limit="47.59" upper_limit="82.41"/>
                    <measurement group_id="O2" value="294.07" lower_limit="226.88" upper_limit="381.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="176.07" lower_limit="144.89" upper_limit="213.96"/>
                    <measurement group_id="O2" value="504.66" lower_limit="435.71" upper_limit="584.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127.11" lower_limit="99.36" upper_limit="162.60"/>
                    <measurement group_id="O2" value="333.24" lower_limit="274.24" upper_limit="404.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="541.81" lower_limit="392.09" upper_limit="748.68"/>
                    <measurement group_id="O2" value="2217.29" lower_limit="1821.95" upper_limit="2698.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5914.33" lower_limit="4710.83" upper_limit="7425.30"/>
                    <measurement group_id="O2" value="14886.35" lower_limit="12560.25" upper_limit="17643.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157.59" lower_limit="118.91" upper_limit="208.84"/>
                    <measurement group_id="O2" value="1415.08" lower_limit="1140.56" upper_limit="1755.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Antibody Concentration (GMC) for Hepatitis B in the 13vPnC Group Relative to the 7vPnC Group After the 2-Dose Infant Series and After Toddler Dose</title>
        <description>GMC of anti-hepatitis B surface antigen (HBsAg)using an Food and Drug Administration (FDA) approved in vitro diagnostic kit.</description>
        <time_frame>One month after the infant series (6 months of age) and the toddler dose (12 months of age)</time_frame>
        <population>Evaluable immunogenicity (per protocol) population had valid and determinate assay results, and had no other major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC After 2-Dose Infant Series</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 3 and 5 months of age (infant series).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC After 2-Dose Infant Series</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with Infanrix hexa at 3 and 5 months of age (infant series).</description>
          </group>
          <group group_id="O3">
            <title>13vPnC After Toddler Dose</title>
            <description>Participants received one single 0.5 mL 13vPnC coadministered with Infanrix hexa at 11 months of age (toddler dose).</description>
          </group>
          <group group_id="O4">
            <title>7vPnC After Toddler Dose</title>
            <description>Participants received one single 0.5 mL 7vPnC coadministered with Infanrix hexa at 11 months of age (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Antibody Concentration (GMC) for Hepatitis B in the 13vPnC Group Relative to the 7vPnC Group After the 2-Dose Infant Series and After Toddler Dose</title>
          <description>GMC of anti-hepatitis B surface antigen (HBsAg)using an Food and Drug Administration (FDA) approved in vitro diagnostic kit.</description>
          <population>Evaluable immunogenicity (per protocol) population had valid and determinate assay results, and had no other major protocol violations.</population>
          <units>mIU/mL</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="273"/>
                <count group_id="O2" value="276"/>
                <count group_id="O3" value="252"/>
                <count group_id="O4" value="255"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="260.46" lower_limit="214.47" upper_limit="316.31"/>
                    <measurement group_id="O2" value="272.67" lower_limit="220.83" upper_limit="336.68"/>
                    <measurement group_id="O3" value="1655.30" lower_limit="1343.30" upper_limit="2039.77"/>
                    <measurement group_id="O4" value="2284.95" lower_limit="1878.82" upper_limit="2778.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Hepatitis b the geometric mean concentration (GMC) ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the geometric mean concentration (GMC)/geometric mean titer (GMT) ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>1.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Hepatitis b the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMC/GMT ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.54</ci_lower_limit>
            <ci_upper_limit>0.96</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Antibody Concentration (GMC) of Haemophilus Influenzae Type b (Hib) in the 13vPnC Group Relative to the 7vPnC Group After the 2-Dose Infant Series and After the Toddler Dose</title>
        <description>GMC for Hib polyribosylribitol phosphate as measured by ELISA, expressed in micrograms per milliliter (μg/mL).</description>
        <time_frame>one month after infant series dose 2 (6 months of age) and after the toddler dose (12 months of age)</time_frame>
        <population>Evaluable immunogenicity (per protocol) population had valid and determinate assay results, and had no other major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC After 2-Dose Infant Series</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 3 and 5 months of age (infant series).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC After 2-Dose Infant Series</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with Infanrix hexa at 3 and 5 months of age (infant series).</description>
          </group>
          <group group_id="O3">
            <title>13vPnC After Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 11 months of age (toddler dose).</description>
          </group>
          <group group_id="O4">
            <title>7vPnC After Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with Infanrix hexa at 11 months of age (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Antibody Concentration (GMC) of Haemophilus Influenzae Type b (Hib) in the 13vPnC Group Relative to the 7vPnC Group After the 2-Dose Infant Series and After the Toddler Dose</title>
          <description>GMC for Hib polyribosylribitol phosphate as measured by ELISA, expressed in micrograms per milliliter (μg/mL).</description>
          <population>Evaluable immunogenicity (per protocol) population had valid and determinate assay results, and had no other major protocol violations.</population>
          <units>μg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="231"/>
                <count group_id="O2" value="267"/>
                <count group_id="O3" value="235"/>
                <count group_id="O4" value="218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.99" lower_limit="0.80" upper_limit="1.21"/>
                    <measurement group_id="O2" value="1.00" lower_limit="0.83" upper_limit="1.20"/>
                    <measurement group_id="O3" value="9.09" lower_limit="7.80" upper_limit="10.60"/>
                    <measurement group_id="O4" value="8.85" lower_limit="7.37" upper_limit="10.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>or Haemophilus influenzae type b the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMC/GMT ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>1.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Haemophilus influenzae type b the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMC/GMT ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.30</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Antibody Concentration (GMC) of Diptheria and Tetanus in the 13vPnC Group Relative to the 7vPnC Group After the 2-Dose Infant Series and After the Toddler Dose</title>
        <description>GMC of anti-diphtheria and anti-tetanus toxoids as measured by ELISA (IU/mL).</description>
        <time_frame>one month after infant series dose 2 (6 months of age) and after the toddler dose (12 months of age)</time_frame>
        <population>Evaluable immunogenicity (per protocol) population had valid and determinate assay results, and had no other major protocol violations; (n) = number of participants with a determinate antibody concentration/titer for the specified concomitant antigen.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC After 2-Dose Infant Series</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 3 and 5 months of age (infant series).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC After 2-Dose Infant Series</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with Infanrix hexa at 3 and 5 months of age (infant series).</description>
          </group>
          <group group_id="O3">
            <title>13vPnC After Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 11 months of age (toddler dose).</description>
          </group>
          <group group_id="O4">
            <title>7vPnC After Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with Infanrix hexa at 11 months of age (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Antibody Concentration (GMC) of Diptheria and Tetanus in the 13vPnC Group Relative to the 7vPnC Group After the 2-Dose Infant Series and After the Toddler Dose</title>
          <description>GMC of anti-diphtheria and anti-tetanus toxoids as measured by ELISA (IU/mL).</description>
          <population>Evaluable immunogenicity (per protocol) population had valid and determinate assay results, and had no other major protocol violations; (n) = number of participants with a determinate antibody concentration/titer for the specified concomitant antigen.</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="275"/>
                <count group_id="O2" value="279"/>
                <count group_id="O3" value="254"/>
                <count group_id="O4" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Diptheria (n=207,240,164,190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.52" lower_limit="0.46" upper_limit="0.60"/>
                    <measurement group_id="O2" value="0.67" lower_limit="0.59" upper_limit="0.76"/>
                    <measurement group_id="O3" value="2.77" lower_limit="2.45" upper_limit="3.13"/>
                    <measurement group_id="O4" value="3.71" lower_limit="3.28" upper_limit="4.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tetanus (n=155,214,125,96)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.53" lower_limit="0.45" upper_limit="0.63"/>
                    <measurement group_id="O2" value="0.63" lower_limit="0.53" upper_limit="0.74"/>
                    <measurement group_id="O3" value="2.62" lower_limit="2.12" upper_limit="3.25"/>
                    <measurement group_id="O4" value="2.09" lower_limit="1.56" upper_limit="2.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For diphtheria toxoid the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMC/GMT ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>0.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Tetanus the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMC/GMT ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For diphtheria toxoid the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMC/GMT ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>0.89</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Tetanus the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMC/GMT ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>1.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.79</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Antibody Concentration (GMC) of Polio Types 1, 2, and 3 in the 13vPnC Group Relative to the 7vPnC Group After the 2-Dose Infant Series and After the Toddler Dose</title>
        <description>GMC of Polio as measured using a polio in vitro plaque neutralization.</description>
        <time_frame>one month after infant series dose 2 (6 months of age) and after the toddler dose (12 months of age)</time_frame>
        <population>Evaluable immunogenicity (per protocol) population had valid and determinate assay results, and had no other major protocol violations; (n) = number of participants with a determinate antibody concentration/titer for the specified concomitant antigen.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC After 2-Dose Infant Series</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 3 and 5 months of age (infant series).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC After 2-Dose Infant Series</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with Infanrix hexa at 3 and 5 months of age (infant series).</description>
          </group>
          <group group_id="O3">
            <title>13vPnC After Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 11 months of age (toddler dose).</description>
          </group>
          <group group_id="O4">
            <title>7vPnC After Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with Infanrix hexa at 11 months of age (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Antibody Concentration (GMC) of Polio Types 1, 2, and 3 in the 13vPnC Group Relative to the 7vPnC Group After the 2-Dose Infant Series and After the Toddler Dose</title>
          <description>GMC of Polio as measured using a polio in vitro plaque neutralization.</description>
          <population>Evaluable immunogenicity (per protocol) population had valid and determinate assay results, and had no other major protocol violations; (n) = number of participants with a determinate antibody concentration/titer for the specified concomitant antigen.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="275"/>
                <count group_id="O2" value="279"/>
                <count group_id="O3" value="254"/>
                <count group_id="O4" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Polio Type 1 (n=207,262,156,179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="180.72" lower_limit="154.31" upper_limit="211.64"/>
                    <measurement group_id="O2" value="207.17" lower_limit="178.64" upper_limit="240.25"/>
                    <measurement group_id="O3" value="924.52" lower_limit="782.71" upper_limit="1092.03"/>
                    <measurement group_id="O4" value="1348.04" lower_limit="1163.56" upper_limit="1561.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Polio Type 2 (n=205,262,153,175)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123.74" lower_limit="102.68" upper_limit="149.13"/>
                    <measurement group_id="O2" value="130.39" lower_limit="109.96" upper_limit="154.63"/>
                    <measurement group_id="O3" value="1141.62" lower_limit="958.68" upper_limit="1359.47"/>
                    <measurement group_id="O4" value="1340.51" lower_limit="1147.88" upper_limit="1565.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Polio Type 3 (n=205,262,153,178)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="397.32" lower_limit="327.00" upper_limit="482.76"/>
                    <measurement group_id="O2" value="452.14" lower_limit="382.57" upper_limit="534.35"/>
                    <measurement group_id="O3" value="1567.64" lower_limit="1289.72" upper_limit="1905.45"/>
                    <measurement group_id="O4" value="2421.31" lower_limit="2072.82" upper_limit="2828.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Polio Type 1 the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMC/GMT ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Polio Type 2 the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMC/GMT ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>1.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Polio Type 3 the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMC/GMT ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Polio Type 1 the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMC/GMT ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>0.86</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Polio Type 2 the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMC/GMT ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Polio Type 3 the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMC/GMT ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.51</ci_lower_limit>
            <ci_upper_limit>0.83</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving an Antibody Level of ≥0.35 μg/mL in the 13vPnC Group After the 2-Dose Infant Series and Before the Toddler Dose</title>
        <description>Percentages of Participants achieving World Health Organization (WHO) predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
        <time_frame>one month after infant series dose 2 (6 months of age) and before the toddler dose (11 months of age)</time_frame>
        <population>The evaluable pneumococcal immunogenicity (per protocol) population was the primary analysis population consisting of eligible subjects who adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC After 2-Dose Infant Series</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 3 and 5 months of age (infant series).</description>
          </group>
          <group group_id="O2">
            <title>13vPnC Before Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 11 months of age (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving an Antibody Level of ≥0.35 μg/mL in the 13vPnC Group After the 2-Dose Infant Series and Before the Toddler Dose</title>
          <description>Percentages of Participants achieving World Health Organization (WHO) predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
          <population>The evaluable pneumococcal immunogenicity (per protocol) population was the primary analysis population consisting of eligible subjects who adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="265"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common Serotypes - Serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.6" lower_limit="93.6" upper_limit="98.4"/>
                    <measurement group_id="O2" value="66.9" lower_limit="60.6" upper_limit="72.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.4" lower_limit="52.2" upper_limit="64.4"/>
                    <measurement group_id="O2" value="76.3" lower_limit="70.3" upper_limit="81.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.7" lower_limit="91.2" upper_limit="97.1"/>
                    <measurement group_id="O2" value="70.5" lower_limit="64.2" upper_limit="76.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.2" lower_limit="90.6" upper_limit="96.7"/>
                    <measurement group_id="O2" value="94.4" lower_limit="90.6" upper_limit="97.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.4" lower_limit="88.5" upper_limit="95.3"/>
                    <measurement group_id="O2" value="53.0" lower_limit="46.4" upper_limit="59.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.1" lower_limit="91.7" upper_limit="97.3"/>
                    <measurement group_id="O2" value="92.4" lower_limit="88.2" upper_limit="95.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.6" lower_limit="62.6" upper_limit="74.1"/>
                    <measurement group_id="O2" value="32.3" lower_limit="26.4" upper_limit="38.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.6" lower_limit="93.6" upper_limit="98.4"/>
                    <measurement group_id="O2" value="83.4" lower_limit="78.0" upper_limit="87.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.8" lower_limit="89.0" upper_limit="95.6"/>
                    <measurement group_id="O2" value="30.8" lower_limit="24.9" upper_limit="37.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.6" lower_limit="87.5" upper_limit="94.6"/>
                    <measurement group_id="O2" value="87.3" lower_limit="82.4" upper_limit="91.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.5" lower_limit="81.8" upper_limit="90.4"/>
                    <measurement group_id="O2" value="86.4" lower_limit="81.4" upper_limit="90.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.5" lower_limit="96.2" upper_limit="99.6"/>
                    <measurement group_id="O2" value="90.7" lower_limit="86.3" upper_limit="94.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.5" lower_limit="96.1" upper_limit="99.6"/>
                    <measurement group_id="O2" value="96.2" lower_limit="92.9" upper_limit="98.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody in 13vPnC Group After the 2-Dose Infant Series and Before Toddler Dose</title>
        <description>Antibody GMC for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
        <time_frame>One month after infant series dose 2 (6 months of age) and before the toddler dose (11 months of age)</time_frame>
        <population>Evaluable pneumococcal immunogenicity (per protocol) had valid and determinate assay results, and had no other major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC After 2-Dose Infant Series</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 3 and 5 months of age (infant series).</description>
          </group>
          <group group_id="O2">
            <title>13vPnC Before Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 11 months of age (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody in 13vPnC Group After the 2-Dose Infant Series and Before Toddler Dose</title>
          <description>Antibody GMC for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
          <population>Evaluable pneumococcal immunogenicity (per protocol) had valid and determinate assay results, and had no other major protocol violations.</population>
          <units>μg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="265"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common Serotypes - Serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.38" lower_limit="2.11" upper_limit="2.67"/>
                    <measurement group_id="O2" value="0.53" lower_limit="0.48" upper_limit="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.41" lower_limit="0.36" upper_limit="0.47"/>
                    <measurement group_id="O2" value="0.61" lower_limit="0.54" upper_limit="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.68" lower_limit="1.51" upper_limit="1.86"/>
                    <measurement group_id="O2" value="0.48" lower_limit="0.43" upper_limit="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.84" lower_limit="2.44" upper_limit="3.31"/>
                    <measurement group_id="O2" value="2.03" lower_limit="1.79" upper_limit="2.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.72" lower_limit="1.54" upper_limit="1.93"/>
                    <measurement group_id="O2" value="0.35" lower_limit="0.32" upper_limit="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.42" lower_limit="2.95" upper_limit="3.97"/>
                    <measurement group_id="O2" value="0.94" lower_limit="0.83" upper_limit="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.61" lower_limit="0.53" upper_limit="0.71"/>
                    <measurement group_id="O2" value="0.26" lower_limit="0.23" upper_limit="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.30" lower_limit="2.03" upper_limit="2.60"/>
                    <measurement group_id="O2" value="0.68" lower_limit="0.61" upper_limit="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.15" lower_limit="1.04" upper_limit="1.28"/>
                    <measurement group_id="O2" value="0.25" lower_limit="0.22" upper_limit="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.27" lower_limit="1.14" upper_limit="1.41"/>
                    <measurement group_id="O2" value="0.88" lower_limit="0.80" upper_limit="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.17" lower_limit="1.02" upper_limit="1.33"/>
                    <measurement group_id="O2" value="0.81" lower_limit="0.72" upper_limit="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.06" lower_limit="1.88" upper_limit="2.26"/>
                    <measurement group_id="O2" value="0.76" lower_limit="0.70" upper_limit="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.87" lower_limit="2.55" upper_limit="3.24"/>
                    <measurement group_id="O2" value="1.20" lower_limit="1.06" upper_limit="1.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving an Antibody Level of ≥0.35 μg/mL in the 13vPnC Relative to the 7vPnC Group After the Toddler Dose</title>
        <description>Percentages of Participants achieving WHO predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
        <time_frame>One month after the toddler dose (12 months of age)</time_frame>
        <population>Evaluable pneumococcal immunogenicity (per protocol) population had valid and determinate assay results, and had no other major protocol violations; (n) = number of participants with a determinate IgG antibody concentration to the given serotype.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC After Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 11 months of age (toddler dose).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC After Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with Infanrix hexa at 11 months of age (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving an Antibody Level of ≥0.35 μg/mL in the 13vPnC Relative to the 7vPnC Group After the Toddler Dose</title>
          <description>Percentages of Participants achieving WHO predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
          <population>Evaluable pneumococcal immunogenicity (per protocol) population had valid and determinate assay results, and had no other major protocol violations; (n) = number of participants with a determinate IgG antibody concentration to the given serotype.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="246"/>
                <count group_id="O2" value="249"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common Serotypes - Serotype 4 (n=244,245)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="98.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 6B (n=243,243)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="98.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 9V (n=235,248)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.4" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="98.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 14 (n=237,240)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.6" lower_limit="97.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.6" lower_limit="97.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 18C (n=245,245)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.2" lower_limit="97.1" upper_limit="99.9"/>
                    <measurement group_id="O2" value="99.6" lower_limit="97.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 19F (n=243,245)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.8" lower_limit="96.4" upper_limit="99.7"/>
                    <measurement group_id="O2" value="98.4" lower_limit="95.9" upper_limit="99.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 23F (n=240,243)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.2" lower_limit="97.0" upper_limit="99.9"/>
                    <measurement group_id="O2" value="98.8" lower_limit="96.4" upper_limit="99.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 1 (n=244,240)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.6" lower_limit="97.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="3.3" lower_limit="1.4" upper_limit="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 3 (n=245,218)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.9" lower_limit="90.1" upper_limit="96.5"/>
                    <measurement group_id="O2" value="6.7" lower_limit="3.9" upper_limit="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 5 (n=245,243)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="70.2" lower_limit="63.6" upper_limit="76.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 6A (n=243,243)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.6" lower_limit="97.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="86.4" lower_limit="81.5" upper_limit="90.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 7F (n=242,243)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.6" lower_limit="97.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="4.9" lower_limit="2.6" upper_limit="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 19A (n=241,241)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.6" lower_limit="97.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody in 13vPnC Relative to 7vPnC Group After the Toddler Dose</title>
        <description>Antibody GMC for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
        <time_frame>One month after toddler dose (12 months of age)</time_frame>
        <population>Evaluable pneumococcal immunogenicity (per protocol) had valid and determinate assay results, and had no other major protocol violations; (n) = number of participants with a determinate antibody concentration for the specified serotype.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC After Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC After Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with Infanrix hexa at 12 months of age (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody in 13vPnC Relative to 7vPnC Group After the Toddler Dose</title>
          <description>Antibody GMC for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
          <population>Evaluable pneumococcal immunogenicity (per protocol) had valid and determinate assay results, and had no other major protocol violations; (n) = number of participants with a determinate antibody concentration for the specified serotype.</population>
          <units>μg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="246"/>
                <count group_id="O2" value="249"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common Serotypes - Serotype 4 (n=244,245)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.77" lower_limit="4.29" upper_limit="5.30"/>
                    <measurement group_id="O2" value="7.08" lower_limit="6.41" upper_limit="7.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 6B (n=243,243)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.00" lower_limit="8.79" upper_limit="11.38"/>
                    <measurement group_id="O2" value="10.39" lower_limit="9.14" upper_limit="11.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 9V (n=235,248)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.02" lower_limit="2.74" upper_limit="3.32"/>
                    <measurement group_id="O2" value="4.10" lower_limit="3.72" upper_limit="4.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 14 (n=237,240)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.30" lower_limit="9.26" upper_limit="11.47"/>
                    <measurement group_id="O2" value="11.99" lower_limit="10.77" upper_limit="13.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 18C (n=245,247)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.83" lower_limit="2.55" upper_limit="3.14"/>
                    <measurement group_id="O2" value="4.26" lower_limit="3.85" upper_limit="4.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 19F (n=243,245)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.01" lower_limit="7.84" upper_limit="10.36"/>
                    <measurement group_id="O2" value="8.06" lower_limit="7.06" upper_limit="9.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 23F (n=244,245)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.43" lower_limit="3.02" upper_limit="3.88"/>
                    <measurement group_id="O2" value="4.87" lower_limit="4.30" upper_limit="5.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 1 (n=244,240)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.76" lower_limit="5.12" upper_limit="6.47"/>
                    <measurement group_id="O2" value="0.03" lower_limit="0.03" upper_limit="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 3 (n=245,240)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.22" lower_limit="1.09" upper_limit="1.35"/>
                    <measurement group_id="O2" value="0.07" lower_limit="0.06" upper_limit="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 5 (n=245,218)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.59" lower_limit="3.25" upper_limit="3.96"/>
                    <measurement group_id="O2" value="0.56" lower_limit="0.49" upper_limit="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 6A (n=243,243)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.78" lower_limit="6.04" upper_limit="7.61"/>
                    <measurement group_id="O2" value="1.42" lower_limit="1.21" upper_limit="1.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 7F (n=242,243)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.31" lower_limit="3.94" upper_limit="4.72"/>
                    <measurement group_id="O2" value="0.04" lower_limit="0.04" upper_limit="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 19F (n=241,241)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.81" lower_limit="8.82" upper_limit="10.92"/>
                    <measurement group_id="O2" value="4.24" lower_limit="3.85" upper_limit="4.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>13vPnC Infant Series</title>
          <description>Participants received one single 0.5mL dose of 13vPnC coadministered with Infanrix hexa at 3 and 5 months. Adverse events were collected from dose 1 to approximately one month after dose 2.</description>
        </group>
        <group group_id="E2">
          <title>7vPnC Infant Series</title>
          <description>Participants received one single 0.5mL dose of 7vPnC coadministered with Infanrix hexa at 3 and 5 months. Adverse events were collected from dose 1 to approximately one month after dose 2.</description>
        </group>
        <group group_id="E3">
          <title>13vPnC Post-Infant Series</title>
          <description>Participants received one single 0.5mL dose of 13vPnC coadministered with Infanrix hexa at 3 and 5 months. Adverse events were collected from approximately one month after dose 2 to toddler dose.</description>
        </group>
        <group group_id="E4">
          <title>7vPnC Post-Infant Series</title>
          <description>Participants received one single 0.5mL dose of 7vPnC coadministered with Infanrix hexa at 3 and 5 months. Adverse events were collected from approximately one month after dose 2 to toddler dose.</description>
        </group>
        <group group_id="E5">
          <title>13vPnC Toddler Series</title>
          <description>Participants received one single 0.5mL dose of 13vPnC at 11 months of age. Adverse events were collected for approximately one month after toddler dose.</description>
        </group>
        <group group_id="E6">
          <title>7vPnC Toddler Series</title>
          <description>Participants received one single 0.5mL dose of 7vPnC at 11 months of age. Adverse events were collected for approximately one month after toddler dose.</description>
        </group>
        <group group_id="E7">
          <title>13vPnC 6-Month Follow-up</title>
          <description>Participants received one single 0.5mL dose of 13vPnC coadministered with Infanrix hexa at 3 and 5 months (infant series) and 11 months of age (toddler dose). Adverse events were collected for approximately six months after last visit.</description>
        </group>
        <group group_id="E8">
          <title>7vPnC 6-Month Follow-up</title>
          <description>Participants received one single 0.5mL dose of 7vPnC coadministered with Infanrix hexa at 3 and 5 months (infant series) and 11 months of age (toddler dose). Adverse events were collected for approximately six months after last visit.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="11" subjects_at_risk="288"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Microcytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="288"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Pelizaeus-Merzbacher disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Cellulitis orbital</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Epstein-Barr virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Gastroenteritis adenovirus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Kawasaki's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Otits media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Parainfluenzae virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="288"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Hypokinesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Infantile spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Meningism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Nystagmus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Syncope vasovagal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Crying</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Decreased activity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Laryngospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="188" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="183" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="96" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="90" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="165" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="170" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Thyroid cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Frequent bowel movements</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Gingival pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Infantile colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Perianal erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Regurgitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title vocab="Systemic Events">Fever ≥38°C but ≤39°C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 1 Infant Series &amp; Toddler Dose</description>
                <counts group_id="E1" subjects_affected="103" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="95" subjects_at_risk="246"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="130" subjects_at_risk="204"/>
                <counts group_id="E6" subjects_affected="103" subjects_at_risk="197"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever ≥38°C but ≤39°C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 2 Infant Series</description>
                <counts group_id="E1" subjects_affected="126" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="137" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;39°C but ≤40°C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 1 Infant Series &amp; Toddler Dose</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="167"/>
                <counts group_id="E6" subjects_affected="20" subjects_at_risk="160"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;39°C but ≤40°C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 2 Infant Series</description>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;40°C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 1 Infant Series &amp; Toddler Dose</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;40°C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 2 Infant Series</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased appetite</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 1 Infant Series &amp; Toddler Dose</description>
                <counts group_id="E1" subjects_affected="87" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="103" subjects_at_risk="198"/>
                <counts group_id="E6" subjects_affected="113" subjects_at_risk="197"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased appetite</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 2 Infant Series</description>
                <counts group_id="E1" subjects_affected="104" subjects_at_risk="220"/>
                <counts group_id="E2" subjects_affected="99" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Irritability</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 1 Infant Series &amp; Toddler Dose</description>
                <counts group_id="E1" subjects_affected="188" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="165" subjects_at_risk="259"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="165" subjects_at_risk="221"/>
                <counts group_id="E6" subjects_affected="170" subjects_at_risk="227"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Irritability</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 2 Infant Series</description>
                <counts group_id="E1" subjects_affected="185" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="183" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Increased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 1 Infant Series &amp; Toddler Dose</description>
                <counts group_id="E1" subjects_affected="177" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="178" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="105" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="107" subjects_at_risk="196"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Increased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 2 Infant Series</description>
                <counts group_id="E1" subjects_affected="129" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="131" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 1 Infant Series &amp; Toddler Dose</description>
                <counts group_id="E1" subjects_affected="96" subjects_at_risk="244"/>
                <counts group_id="E2" subjects_affected="88" subjects_at_risk="242"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="64" subjects_at_risk="180"/>
                <counts group_id="E6" subjects_affected="61" subjects_at_risk="171"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 2 Infant Series</description>
                <counts group_id="E1" subjects_affected="89" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="89" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="34" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatomegaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Exanthema subitum</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Viral skin infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Enteritis infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Erythema infectiosum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Hand-foot-and-mouth disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Acute tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Roseola</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nystagmus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary tract pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Genital rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Rhonchi</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title vocab="Local Reaction">Tenderness (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 1 Infant Series &amp; Toddler Dose</description>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="94" subjects_at_risk="199"/>
                <counts group_id="E6" subjects_affected="83" subjects_at_risk="188"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reaction">Tenderness (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 2 Infant Series</description>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="79" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reaction">Tenderness (Significant)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 1 Infant Series &amp; Toddler Dose</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="164"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="153"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reaction">Tenderness (Significant)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 2 Infant Series</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="199"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reaction">Induration (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 1 Infant Series &amp; Toddler Dose</description>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="232"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="50" subjects_at_risk="175"/>
                <counts group_id="E6" subjects_affected="45" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reaction">Induration (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 2 Infant Series</description>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reaction">Induration (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 1 Infant Series &amp; Toddler Dose</description>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="232"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="46" subjects_at_risk="174"/>
                <counts group_id="E6" subjects_affected="35" subjects_at_risk="161"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reaction">Induration (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 2 Infant Series</description>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="208"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reaction">Induration (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 1 Infant Series &amp; Toddler Dose</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="157"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reaction">Induration (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 2 Infant Series</description>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reaction">Induration (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 1 Infant Series &amp; Toddler Dose</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reaction">Induration (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 2 Infant Series</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reaction">Erythema (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 1 Infant Series &amp; Toddler Dose</description>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="65" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="63" subjects_at_risk="174"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reaction">Erythema (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 2 Infant Series</description>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="213"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reaction">Erythema (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 1 Infant Series &amp; Toddler Dose</description>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="244"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="58" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="53" subjects_at_risk="172"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reaction">Erythema (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 2 Infant Series</description>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="211"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="211"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reaction">Erythema (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 1 Infant Series &amp; Toddler Dose</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="17" subjects_at_risk="156"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reaction">Erythema (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 2 Infant Series</description>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reaction">Erythema (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 1 Infant Series &amp; Toddler Dose</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reaction">Erythema (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 2 Infant Series</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Skin fissures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="291"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="288"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>U. S. Contact Center</name_or_title>
      <organization>Wyeth</organization>
      <email>clintrialresults@wyeth.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

